Boston Scientific Corp (BSX)
Debt-to-equity ratio
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Long-term debt | US$ in thousands | — | — | — | — | — |
Total stockholders’ equity | US$ in thousands | 21,770,000 | 19,282,000 | 17,574,000 | 16,623,000 | 15,327,000 |
Debt-to-equity ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
December 31, 2024 calculation
Debt-to-equity ratio = Long-term debt ÷ Total stockholders’ equity
= $—K ÷ $21,770,000K
= 0.00
The debt-to-equity ratio for Boston Scientific Corp has consistently remained at 0.00 for the years 2020, 2021, 2022, 2023, and 2024. This indicates that the company is not relying heavily on debt to finance its operations, and has a strong equity base to support its activities. A debt-to-equity ratio of 0.00 suggests that the company may be financing its operations primarily through equity, which can be viewed positively as it signifies lower financial risk and a healthier financial position.
Peer comparison
Dec 31, 2024
Company name
Symbol
Debt-to-equity ratio
Boston Scientific Corp
BSX
0.00
3M Company
MMM
2.90
Artivion Inc
AORT
0.00
Baxter International Inc
BAX
0.00
Becton Dickinson and Company
BDX
0.69
DexCom Inc
DXCM
0.00
Embecta Corp
EMBC
—
Glaukos Corp
GKOS
0.00
Globus Medical
GMED
0.00
Haemonetics Corporation
HAE
0.83
ICU Medical Inc
ICUI
0.00